Literature DB >> 25144149

Clinical features of docetaxel chemotherapy-related lymphedema.

Sae In Park1, Woo Hyun Jeon, Ho Joong Jeung, Ghi Chan Kim, Dong Kyu Kim, Young-Joo Sim.   

Abstract

Lymphedema is a chronic, progressive, and multifactorial disease. The anticancer drug docetaxel (Taxotere) can lead to fluid retention, which is the main cause of peripheral edema of the extremities, pleural effusion, pericardial effusion, and ascites in patients undergoing chemotherapy. While there have been a few case reports documenting fluid retention-induced edema as a side effect of docetaxel, it is not yet clear whether docetaxel causes lymphedema directly. Here, we report cases of three patients who developed lymphedema after treatment with docetaxel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25144149     DOI: 10.1089/lrb.2013.0037

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  3 in total

1.  Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.

Authors:  Meyha N Swaroop; Chantal M Ferguson; Nora K Horick; Melissa N Skolny; Cynthia L Miller; Lauren S Jammallo; Cheryl L Brunelle; Jean A O'Toole; Steven J Isakoff; Michelle C Specht; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2015-05-05       Impact factor: 4.872

2.  Lymph-Venous Anastomosis for Breast Cancer-Related Lymphoedema after Docetaxel-Based Chemotherapy.

Authors:  Yuma Fuse; Ryo Karakawa; Tomoyuki Yano; Hidehiko Yoshimatsu
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

3.  Systemic treatment in breast cancer: a primer for radiologists.

Authors:  Aya Y Michaels; Abhishek R Keraliya; Sree Harsha Tirumani; Atul B Shinagare; Nikhil H Ramaiya
Journal:  Insights Imaging       Date:  2015-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.